Detail akcie Dyne Therapeutcs Rg online

Business Summary: Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Dyne Therapeutics Inc revenues was not reported. Net loss increased 40% to $235.9M. Higher net loss reflects Research and de increase of 49% to $159.9M (expense), Labor & Related Expenses in R&D increase of 43% to $39.3M (expense), Stock-based Compensation in R&D increase of 41% to $11.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$3.23 to -$3.95.